Clinical Effects of Psychedelic Substances Reported to United States Poison Centers: 2012 to 2022.
Annals of emergency medicine December 1, 2024 Mark W Simon, Heather A Olsen, Christopher O Hoyte et al. 12 citations
Over half of psychedelic exposures reported to US poison centers resulted in symptoms that required treatment, severe residual or prolonged symptoms, or death. From 2012 to 2022, 54,605 cases were recorded, with hallucinogenic mushroom exposures rising most sharply from 593 to 1,440. Cardiovascular effects were common, especially with hallucinogenic amphetamines (31.1%). Among patients managed in healthcare facilities, 62.4% received medical therapies, including sedation (32.9%) and respiratory interventions (10.3%). Concomitant exposures occurred in 41.1% of cases. Increasing psychedelic use may lead to more adverse events and healthcare utilization.